Trial Profile
An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315, a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax, a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia (AML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs S 64315 (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Servier
- 24 Jul 2023 Status changed from discontinued to completed.
- 02 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 04 Nov 2022 Planned End Date changed from 31 Jan 2024 to 13 Mar 2023.